Skip to content

A Multi-centre, Observational Study of Patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network

A Multi-centre, Observational Study by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network To Determine The Clinical Characteristics, Laboratory Features, Treatments, and Clinical Outcomes in Patients with Microangiopathic Thrombocytopenia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12614001073695
Acronym
APMAT 1
Enrollment
81
Registered
2014-10-07
Start date
2015-01-01
Completion date
2022-12-31
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This is an observational study of patients who have previously been diagnosed and treated for Microangiopathic Thrombocytopenia (MAT). The study will collect clinical and laboratory data to assess the disease characteristics, laboratory features, treatments, and clinical outcome.

Interventions

This is an observational study of previously diagnosed and treated microangiopathic thrombocytopenia (MAT) patients. MAT is a rare collection of disorders caused by the formation of intravascular aggregates of platelets resulting in microcirculatory thrombosis, red blood cell destruction and vital end-organ damage. The study will collect clinical and laboratory data to assess the disease characteristics, laboratory features, treatment strategies employed, and clinical outcome. Each participant w

This is an observational study of previously diagnosed and treated microangiopathic thrombocytopenia (MAT) patients. MAT is a rare collection of disorders caused by the formation of intravascular aggregates of platelets resulting in microcirculatory thrombosis, red blood cell destruction and vital end-organ damage. The study will collect clinical and laboratory data to assess the disease characteristics, laboratory features, treatment strategies employed, and clinical outcome. Each participant will be observed for 6 months once they are enrolled in the study.

Sponsors

ASTH
Lead SponsorOther Collaborative groups

Eligibility

Sex/Gender
All
Age
1 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients presenting to a study centre and diagnosed with microangiopathic thrombocytopenia as defined by but not limited to anaemia, thrombocytopenia (<150 x10^9/L) and evidence of fragmented red blood cells (schistocytes) on blood film.

Exclusion criteria

Patients who have non-microangiopathic thrombocytopenia and/or thrombosis where an alternate diagnosis is likely. Patients who are unable or unwilling to provide informed consent.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026